

Moderate to severe ARDS with PF ratio <150 for >48 hours

THE ACURASYS TRIAL

Does early neuromuscular blockade in moderate to severe cases of acute respiratory distress syndrome result in better mortality?

MULTICENTER - DOUBLE-BLINDED - RANDOMIZED



20 centers

CISATRACURIUM


Standard care with protective lung strategy and 48-hour continuous infusion of cisatracurium

178 PATIENTS

PLACEBO

Standard care with protective lung strategy and placebo.

162 PATIENTS



Adjusted Hazard ratio 0.68 (95% C.I. 0.48-0.98), p=0.04

Early use of cisatracurium in patients with moderate-to-severe ARDS improves the adjusted 90-day survival and increased the ventilator-free days without increasing muscle weakness!